Group 1: Camerry New Material Tech Limited (佳美新材) - Camerry New Material Tech Limited has submitted an IPO application to the SEC for listing on NASDAQ under the ticker CNMT, with the initial secret application filed on December 3, 2024 [1] - The company specializes in the production of customized nylon filament products and holds 16 registered trademarks and 21 patents in China as of May 31, 2025 [3] - Financial performance for the fiscal years ending March 31 shows revenues of RMB 94.157 million and RMB 114.706 million for 2024 and 2025 respectively, with net income increasing from RMB 5.876 million to RMB 8.379 million [3] Group 2: Shareholding Structure - Prior to the IPO, Wenyu Lin holds 88% of the ordinary shares, controlling 98.3% of the voting rights, while Yifan Zhang owns 5.3% of Class A shares with 0.7% voting rights [7] - Principal shareholders include Saturn Investment Co., Ltd with 82.7% ownership and Ever-Rise Co., Ltd with 5.3% ownership [7] Group 3: MENS Biotechnology (健永生技) - MENS Biotechnology has successfully listed on NASDAQ with the ticker MENS, opening at $15 per share, a 100% increase from the offering price, and closing at $10.11, reflecting a 34.80% gain [8][10] - The company issued 2.67 million shares at an offering price of $7.5 per share, raising $20 million, which will be allocated for R&D and clinical trials [10] - MENS focuses on urological diseases, with its main candidate drug MCS-2 currently under development for benign prostatic hyperplasia and lower urinary tract symptoms, reporting net losses of $66.3 million, $4.4 million, and $1.326 million for the years 2022-2023 and the first half of 2024 [10]